AR040868A1 - Proceso para la fabricacion de sal de calcio del acido (e)-7-[4-(4-fluorofenil)-6-isopropil-2-[metil (metilsulfonil) amino] piridin-5-il] (3r,5s)-3,5-dihidroxihept-6-enoico y producto que se obtiene a partir del mismo - Google Patents
Proceso para la fabricacion de sal de calcio del acido (e)-7-[4-(4-fluorofenil)-6-isopropil-2-[metil (metilsulfonil) amino] piridin-5-il] (3r,5s)-3,5-dihidroxihept-6-enoico y producto que se obtiene a partir del mismoInfo
- Publication number
- AR040868A1 AR040868A1 AR20030102929A ARP030102929A AR040868A1 AR 040868 A1 AR040868 A1 AR 040868A1 AR 20030102929 A AR20030102929 A AR 20030102929A AR P030102929 A ARP030102929 A AR P030102929A AR 040868 A1 AR040868 A1 AR 040868A1
- Authority
- AR
- Argentina
- Prior art keywords
- fluorophenyl
- amino
- methyl
- manufacture
- product obtained
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Un proceso mejorado para la fabricación de sal de calcio del ácido (E)-7-[4-(4-fluorofenil)-6-isopropil-2-[metil(metilsulfonil)amino]pirimidin-5-il](3R,5S)-3,5-dihidroxihept-6-enoico, de la siguiente fórmula (1). En este proceso se mezcla una solución de cloruro de calcio con una solución de una sal soluble en agua del ácido (1); en el proceso los parámetros de selección para dar un producto que demuestra mayor eficiencia de filtración. Este compuesto es útil para la producción de una composición farmacéutica que se utiliza en el tratamiento de, entre otras afecciones, la hipercolesterolemia, la hiperlipoproteinemia y la ateroesclerosis. También se describe el producto que se obtiene a partir de dicho proceso.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0218781.3A GB0218781D0 (en) | 2002-08-13 | 2002-08-13 | Chemical process |
Publications (1)
Publication Number | Publication Date |
---|---|
AR040868A1 true AR040868A1 (es) | 2005-04-20 |
Family
ID=9942204
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AR20030102929A AR040868A1 (es) | 2002-08-13 | 2003-08-13 | Proceso para la fabricacion de sal de calcio del acido (e)-7-[4-(4-fluorofenil)-6-isopropil-2-[metil (metilsulfonil) amino] piridin-5-il] (3r,5s)-3,5-dihidroxihept-6-enoico y producto que se obtiene a partir del mismo |
Country Status (30)
Country | Link |
---|---|
US (2) | US7511140B2 (es) |
EP (1) | EP1539711B1 (es) |
JP (1) | JP4588446B2 (es) |
KR (1) | KR101325827B1 (es) |
CN (1) | CN100361979C (es) |
AR (1) | AR040868A1 (es) |
AT (1) | ATE501125T1 (es) |
AU (1) | AU2003251369B2 (es) |
BR (1) | BR0313394A (es) |
CA (1) | CA2495296C (es) |
CY (1) | CY1112412T1 (es) |
DE (1) | DE60336326D1 (es) |
DK (1) | DK1539711T3 (es) |
ES (1) | ES2361009T3 (es) |
GB (1) | GB0218781D0 (es) |
HK (1) | HK1082735A1 (es) |
IL (1) | IL166626A (es) |
IS (1) | IS7728A (es) |
MX (1) | MXPA05001582A (es) |
MY (1) | MY135301A (es) |
NO (1) | NO329439B1 (es) |
NZ (1) | NZ538070A (es) |
PL (1) | PL375296A1 (es) |
PT (1) | PT1539711E (es) |
RU (1) | RU2326871C2 (es) |
SI (1) | SI1539711T1 (es) |
TW (1) | TWI316058B (es) |
UA (1) | UA83805C2 (es) |
WO (1) | WO2004014872A1 (es) |
ZA (1) | ZA200500745B (es) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6733780B1 (en) | 1999-10-19 | 2004-05-11 | Genzyme Corporation | Direct compression polymer tablet core |
GB0003305D0 (en) | 2000-02-15 | 2000-04-05 | Zeneca Ltd | Pyrimidine derivatives |
GB0011120D0 (en) | 2000-05-09 | 2000-06-28 | Avecia Ltd | Process |
NL1015744C2 (nl) | 2000-07-19 | 2002-01-22 | Dsm Nv | Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten. |
CN100349877C (zh) * | 2001-07-13 | 2007-11-21 | 阿斯特拉曾尼卡英国有限公司 | 氨基嘧啶化合物的制备方法 |
EP1323717A1 (en) | 2001-12-27 | 2003-07-02 | Dsm N.V. | Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives |
EP1375493A1 (en) | 2002-06-17 | 2004-01-02 | Dsm N.V. | Process for the preparation of an dioxane acetic acid ester |
GB0218781D0 (en) * | 2002-08-13 | 2002-09-18 | Astrazeneca Ab | Chemical process |
DE60330050D1 (de) | 2002-12-16 | 2009-12-24 | Astrazeneca Uk Ltd | Verfahren zur herstellung von pyrimidinverbindungen |
GB0312896D0 (en) * | 2003-06-05 | 2003-07-09 | Astrazeneca Ab | Chemical process |
WO2005023778A2 (en) * | 2003-08-28 | 2005-03-17 | Teva Pharmaceutical Industries Ltd. | Process for preparation of rosuvastatin calcium |
UY28501A1 (es) | 2003-09-10 | 2005-04-29 | Astrazeneca Uk Ltd | Compuestos químicos |
GB0321827D0 (en) * | 2003-09-18 | 2003-10-15 | Astrazeneca Uk Ltd | Chemical compounds |
GB0324791D0 (en) * | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Chemical process |
TW200526596A (en) | 2003-11-24 | 2005-08-16 | Teva Pharma | Crystalline ammonium salts of rosuvastatin |
EP1689723B1 (en) * | 2003-12-02 | 2011-04-27 | Teva Pharmaceutical Industries, Ltd. | Reference standard for characterization of rosuvastatin |
EP1737828A1 (en) * | 2004-01-19 | 2007-01-03 | Ranbaxy Laboratories Limited | Amorphous magnesium salts of rosuvastatin |
US7241800B2 (en) | 2004-03-17 | 2007-07-10 | Mai De Ltd. | Anhydrous amorphous form of fluvastatin sodium |
WO2006017357A1 (en) | 2004-07-13 | 2006-02-16 | Teva Pharmaceutical Industries Ltd. | A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step |
WO2006035277A2 (en) * | 2004-09-27 | 2006-04-06 | Ranbaxy Laboratories Limited | Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium |
US7985418B2 (en) | 2004-11-01 | 2011-07-26 | Genzyme Corporation | Aliphatic amine polymer salts for tableting |
ATE479662T1 (de) * | 2004-12-23 | 2010-09-15 | Hui Yao | Pyrimidinonverbindungen, ihre herstellung und ihre verwendung |
GB0428328D0 (en) * | 2004-12-24 | 2005-02-02 | Astrazeneca Uk Ltd | Chemical process |
US7932387B2 (en) * | 2005-01-31 | 2011-04-26 | Basf Se | Crystalline forms of rosuvastatin calcium salt |
WO2006091771A2 (en) | 2005-02-22 | 2006-08-31 | Teva Pharmaceutical Industries Ltd. | Preparation of rosuvastatin |
JP5416403B2 (ja) | 2005-06-24 | 2014-02-12 | レツク・フアーマシユーテイカルズ・デー・デー | 純粋な非結晶ロスバスタチンカルシウムの調製方法 |
CN101208307B (zh) * | 2005-06-24 | 2012-10-17 | 力奇制药公司 | 制备不含杂质的无定型罗苏伐他汀钙的方法 |
GB0514078D0 (en) * | 2005-07-08 | 2005-08-17 | Astrazeneca Uk Ltd | Chemical process |
AU2006278444A1 (en) * | 2005-08-04 | 2007-02-15 | Transform Pharmaceuticals, Inc. | Novel formulations comprising fenofibrate and a statin, and related methods of treatment |
WO2007022488A2 (en) | 2005-08-16 | 2007-02-22 | Teva Pharmaceutical Industries Ltd. | Crystalline rosuvastatin intermediate |
TW200800918A (en) | 2005-08-16 | 2008-01-01 | Teva Pharma | Rosuvastatin calcium with a low salt content |
PT1924246E (pt) | 2005-09-15 | 2016-02-10 | Genzyme Corp | Formulação sachê para polímeros com funcionalidade amina |
US8455640B2 (en) | 2006-05-03 | 2013-06-04 | Msn Laboratories Limited | Process for statins and its pharmaceutically acceptable salts thereof |
EP2086945B1 (en) | 2006-10-09 | 2016-01-06 | MSN Laboratories Private Limited | Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof |
EP2079712A2 (en) | 2006-10-31 | 2009-07-22 | Aurobindo Pharma Limited | An improved process for preparing rosuvastatin calcium |
TW200831469A (en) * | 2006-12-01 | 2008-08-01 | Astrazeneca Uk Ltd | Chemical process |
WO2008072078A1 (en) | 2006-12-13 | 2008-06-19 | Aurobindo Pharma Limited | An improved process for preparing rosuvastatin caclium |
AU2008212622B2 (en) | 2007-02-08 | 2011-01-27 | Aurobindo Pharma Limited | An improved process for preparation of rosuvastatin calcium |
WO2009009153A1 (en) * | 2007-07-12 | 2009-01-15 | Teva Pharmaceutical Industries Ltd. | Purification of rosuvastatin intermediate by thin film evaporation and chemical method |
HU230637B1 (hu) * | 2007-10-12 | 2017-05-29 | Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság | Eljárás rosuvastatin intermedierek előállítására |
HU230981B1 (hu) * | 2007-10-12 | 2019-08-28 | Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság | Eljárás rosuvastatin só előállítására |
EP2298745B1 (en) | 2008-05-27 | 2014-09-03 | Changzhou Pharmaceutical Factory | Preparation method of rosuvastatin calcium and its intermediates |
WO2010035284A2 (en) * | 2008-09-26 | 2010-04-01 | Matrix Laboratories Ltd | An improved process for the preparation of rosuvastatin calcium |
EP2350025A1 (en) * | 2008-09-30 | 2011-08-03 | Aurobindo Pharma Limited | An improved process for preparing pyrimidine propenaldehyde |
EA021942B1 (ru) | 2009-01-15 | 2015-10-30 | Эгиш Дьёдьсердьяр Зрт. | Способ изготовления солей розувастатина |
EP2387561A4 (en) | 2009-01-19 | 2012-07-25 | Msn Lab Ltd | IMPROVED PROCESS FOR THE PREPARATION OF HIGH-PURITY (3R, 5S) -7-β-CYCLOPROPYL-4- (4-FLUOROPHENYL) QUINOLIN-3-YL-3,5-DIHYDROXY-6 (E) -HEPTENOIC ACID, INCLUDING ITS PHARMACEUTICALLY ACCEPTABLE SALTS |
WO2011086584A2 (en) | 2010-01-18 | 2011-07-21 | Msn Laboratories Limited | Improved process for the preparation of amide intermediates and their use thereof |
AU2011243948B2 (en) | 2010-04-23 | 2014-07-17 | Sun Pharmaceutical Industries Limited | Novel intermediates for the preparation of HMG-CoA reductase inhibitors |
HU230987B1 (hu) | 2010-11-29 | 2019-08-28 | Egis Gyógyszergyár Nyrt. | Eljárás nagy tisztaságú gyógyszeripari intermedierek előállítására |
US9676729B2 (en) * | 2013-03-29 | 2017-06-13 | Dsm Sinochem Pharmaceuticals Netherlands B.V. | Amine salts of pitavastatin and rosuvastatin |
TWM477638U (zh) * | 2013-12-12 | 2014-05-01 | 三緯國際立體列印科技股份有限公司 | 加熱平台與立體列印裝置 |
BR112019015107A2 (pt) | 2017-01-23 | 2020-03-10 | Dong Wha Pharm. Co., Ltd. | Formulação de complexo compreendendo inibidor de hmg-coa redutase e clopidogrel |
MX2021014552A (es) | 2019-05-27 | 2022-02-11 | Immatics Us Inc | Vectores viricos y uso de los mismos en terapias celulares adoptivas. |
DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
US20220056411A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
SI26268A (sl) | 2021-11-18 | 2023-05-31 | Zupet Rok | Postopek za pripravo hidratirane oblike perindopril l-arginina |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US663641A (en) * | 1900-10-11 | 1900-12-11 | Charles A Ruebekam | Burial-casket. |
US4645858A (en) | 1982-03-22 | 1987-02-24 | G. D. Searle & Co. | Pentanedioic acid derivatives |
DE3741509A1 (de) | 1987-12-08 | 1989-06-22 | Hoechst Ag | Verfahren zur herstellung optisch aktiver 3-desmethylmevalonsaeurederivate sowie zwischenprodukte |
KR900701778A (ko) | 1988-10-06 | 1990-12-04 | 예안 크라머, 한스 루돌프 하우스 | 피리미디닐- 치환된 하이드록시산, 락톤 및 에스테르, 및 이를 함유하는 약학적 조성물 |
US5026698A (en) | 1988-11-02 | 1991-06-25 | Nissan Chemical Industries, Ltd. | Thienopyridine type mevalonolactones |
JP2648897B2 (ja) * | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
WO1993008823A1 (en) | 1991-11-06 | 1993-05-13 | Tanabe Seiyaku Co., Ltd. | Guanidinyl and related cell adhesion modulation compounds |
US5278313A (en) | 1992-03-27 | 1994-01-11 | E. R. Squibb & Sons, Inc. | Process for the preparation of 1,3-dioxane derivatives useful in the preparation of HMG-COA reductase inhibitors |
DE59307409D1 (de) | 1992-07-02 | 1997-10-30 | Hoechst Ag | Verfahren zur Herstellung von (3R,5S)6-Hydroxy-3,5-0-isopropyliden-3,5-dihydroxy-hexansäure-tert.-butylester |
DE69616808T2 (de) | 1995-07-17 | 2002-05-29 | Warner Lambert Co | Kristallines (r-(r*,r*))-2-(4-fluorphenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrol-1-heptancarbonsäure hemi calcium salz (atorvastatin) |
US6278001B1 (en) | 1995-11-28 | 2001-08-21 | L'oréal | Method for preparing (+) compactin and (+) mevinolin analog compounds having a β-hydroxy-δ-lactone grouping |
FR2741620B1 (fr) | 1995-11-28 | 1997-12-26 | Oreal | Procede de preparation de composes a groupement beta-hydroxy -delta-lactone analogues de la (+) compactine et de la (+) mevinoline |
ATE234282T1 (de) | 1996-06-24 | 2003-03-15 | Novartis Pharma Gmbh | Polymorphe verbindungen |
EP1533308B1 (en) | 1998-12-10 | 2014-01-15 | Kaneka Corporation | A process for producing a simvastatin precursor |
GB9900339D0 (en) | 1999-01-09 | 1999-02-24 | Zeneca Ltd | Chemical compounds |
GB9903472D0 (en) * | 1999-02-17 | 1999-04-07 | Zeneca Ltd | Chemical process |
ATE307120T1 (de) * | 1999-07-13 | 2005-11-15 | Lonza Ag | Verfahren zur herstellung von 2-amino-4(4- fluorphenyl)-6-alkylpyrimidin-5-carbonsäureeste |
WO2001022962A1 (en) | 1999-09-30 | 2001-04-05 | Merck & Co., Inc. | Anti-hypercholesterolemic drug combination |
WO2001036384A1 (en) | 1999-11-17 | 2001-05-25 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
GB0001621D0 (en) | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
GB0003305D0 (en) * | 2000-02-15 | 2000-04-05 | Zeneca Ltd | Pyrimidine derivatives |
WO2001072706A1 (en) | 2000-03-28 | 2001-10-04 | Biocon India Limited | Synthesis of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
GB0011120D0 (en) * | 2000-05-09 | 2000-06-28 | Avecia Ltd | Process |
GB0011163D0 (en) | 2000-05-10 | 2000-06-28 | Astrazeneca Ab | Chemical compound |
NL1015744C2 (nl) | 2000-07-19 | 2002-01-22 | Dsm Nv | Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten. |
PL361230A1 (en) | 2000-10-05 | 2004-10-04 | Biogal Gyogyszergyar Rt. | Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same |
PT1341785E (pt) | 2000-11-16 | 2009-01-16 | Teva Pharma | Hidrólise de ésteres de ácidos r(r*,r*)-2-(4-fluorofenil)-beta,delta-di-hidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)-carbonil]-1h-pirrole-1-heptanóico com hidróxido de cálcio |
US6777552B2 (en) | 2001-08-16 | 2004-08-17 | Teva Pharmaceutical Industries, Ltd. | Processes for preparing calcium salt forms of statins |
IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
NL1017548C2 (nl) | 2001-03-09 | 2002-09-10 | Synthon Bv | Een lactonisatie proces. |
IN190564B (es) | 2001-04-11 | 2003-08-09 | Cadila Heathcare Ltd | |
DE02737324T1 (de) | 2001-06-06 | 2004-07-15 | Bristol-Myers Squibb Co. | Verfahren zur herstellung chiraler diolsulfone und inhibitoren von dihydroxysäure-hmg-coa-reduktase |
CN100349877C (zh) | 2001-07-13 | 2007-11-21 | 阿斯特拉曾尼卡英国有限公司 | 氨基嘧啶化合物的制备方法 |
CA2450820C (en) | 2001-08-16 | 2011-03-15 | Teva Pharmaceutical Industries Ltd. | Processes for preparing calcium salt forms of statins |
JP2005503393A (ja) | 2001-08-22 | 2005-02-03 | チバ スペシャルティ ケミカルズ ホールディング インコーポレーテッド | インドール誘導体の製造方法 |
CA2459926A1 (en) | 2001-09-24 | 2003-04-03 | Merck & Co., Inc. | Screening and selection methods for statin drug combinations |
EP1323717A1 (en) | 2001-12-27 | 2003-07-02 | Dsm N.V. | Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives |
KR100511533B1 (ko) | 2002-04-09 | 2005-08-31 | 임광민 | 키랄 중간체, 그의 제조방법 및 그를 이용한 HMG-CoA환원저해제의 제조방법 |
AR039836A1 (es) | 2002-05-21 | 2005-03-02 | Ranbaxy Lab Ltd | Proceso para la preparacion de un aldehido de pirimidina util para la preparacion de rosuvastatina |
EP1375493A1 (en) | 2002-06-17 | 2004-01-02 | Dsm N.V. | Process for the preparation of an dioxane acetic acid ester |
GB0218781D0 (en) | 2002-08-13 | 2002-09-18 | Astrazeneca Ab | Chemical process |
HUP0500851A3 (en) | 2002-12-10 | 2008-02-28 | Ranbaxy Lab Ltd | Process for the preparation of rosuvastatin |
DE60330050D1 (de) | 2002-12-16 | 2009-12-24 | Astrazeneca Uk Ltd | Verfahren zur herstellung von pyrimidinverbindungen |
BRPI0409292A (pt) | 2003-04-11 | 2006-04-11 | Lek Pharmaceuticals | processo para a preparação de sal de cálcio amorfo de atorvastatina |
WO2004103977A2 (en) | 2003-05-21 | 2004-12-02 | Ciba Specialty Chemicals Holding Inc. | Process for the preparation of pyrimidine derivatives |
GB0312896D0 (en) * | 2003-06-05 | 2003-07-09 | Astrazeneca Ab | Chemical process |
AU2003247327A1 (en) | 2003-07-15 | 2005-01-28 | Eos Eczacibasi Ozgun Kimyasal Urunler Sanyi Ve Ticaret A.S. | Process for the preparation of amortphous atorvastatin calcium without interconversion of any crystalline form |
WO2005023778A2 (en) | 2003-08-28 | 2005-03-17 | Teva Pharmaceutical Industries Ltd. | Process for preparation of rosuvastatin calcium |
UY28501A1 (es) | 2003-09-10 | 2005-04-29 | Astrazeneca Uk Ltd | Compuestos químicos |
GB0321827D0 (en) | 2003-09-18 | 2003-10-15 | Astrazeneca Uk Ltd | Chemical compounds |
GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
WO2005040134A1 (en) | 2003-10-22 | 2005-05-06 | Ranbaxy Laboratories Limited | Process for the preparation of amorphous rosuvastatin calcium |
GB0324791D0 (en) * | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Chemical process |
DE10352659B4 (de) | 2003-11-11 | 2007-09-13 | Ratiopharm Gmbh | Verfahren zur Herstellung von Statinen und Tetrahydropyranonderivate zur Verwendung in dem Verfahren |
US7028631B2 (en) * | 2003-11-24 | 2006-04-18 | The Boeing Company | Gliding submersible transport system |
TW200526596A (en) | 2003-11-24 | 2005-08-16 | Teva Pharma | Crystalline ammonium salts of rosuvastatin |
EP1689723B1 (en) | 2003-12-02 | 2011-04-27 | Teva Pharmaceutical Industries, Ltd. | Reference standard for characterization of rosuvastatin |
WO2005054207A1 (en) | 2003-12-04 | 2005-06-16 | Glenmark Pharmaceuticals Limited | Process for the preparation of pyrimidine derivatives |
KR20060135712A (ko) | 2003-12-24 | 2006-12-29 | 테바 파마슈티컬 인더스트리즈 리미티드 | 높은 syn형 대 anti형 비율을 지닌 스타틴의 제조방법 |
CZ200486A3 (cs) | 2004-01-16 | 2005-08-17 | Zentiva, A.S. | Způsob výroby hemivápenaté soli (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxy-6-heptenové kyseliny |
EP1709008A1 (en) | 2004-01-19 | 2006-10-11 | Ranbaxy Laboratories Limited | Salts of hmg-coa reductase inhibitors and use thereof |
EP1737828A1 (en) | 2004-01-19 | 2007-01-03 | Ranbaxy Laboratories Limited | Amorphous magnesium salts of rosuvastatin |
US7241800B2 (en) | 2004-03-17 | 2007-07-10 | Mai De Ltd. | Anhydrous amorphous form of fluvastatin sodium |
GB0406757D0 (en) | 2004-03-26 | 2004-04-28 | Avecia Ltd | Process and compounds |
US7161004B2 (en) | 2004-06-21 | 2007-01-09 | Dr. Reddy's Laboratories Limited | Processes to produce intermediates for rosuvastatin |
WO2006017357A1 (en) | 2004-07-13 | 2006-02-16 | Teva Pharmaceutical Industries Ltd. | A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step |
WO2006035277A2 (en) | 2004-09-27 | 2006-04-06 | Ranbaxy Laboratories Limited | Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium |
GB0428328D0 (en) * | 2004-12-24 | 2005-02-02 | Astrazeneca Uk Ltd | Chemical process |
US7932387B2 (en) | 2005-01-31 | 2011-04-26 | Basf Se | Crystalline forms of rosuvastatin calcium salt |
CA2498978A1 (en) | 2005-02-28 | 2006-08-28 | Apotex Pharmachem Inc. | An improved process for the preparation of atorvastatin and intermediates |
GB0514078D0 (en) * | 2005-07-08 | 2005-08-17 | Astrazeneca Uk Ltd | Chemical process |
TW200831469A (en) * | 2006-12-01 | 2008-08-01 | Astrazeneca Uk Ltd | Chemical process |
-
2002
- 2002-08-13 GB GBGB0218781.3A patent/GB0218781D0/en not_active Ceased
-
2003
- 2003-07-08 UA UAA200500711A patent/UA83805C2/uk unknown
- 2003-08-07 JP JP2004527041A patent/JP4588446B2/ja not_active Expired - Lifetime
- 2003-08-07 MX MXPA05001582A patent/MXPA05001582A/es active IP Right Grant
- 2003-08-07 RU RU2005102391/04A patent/RU2326871C2/ru active
- 2003-08-07 DK DK03784274.7T patent/DK1539711T3/da active
- 2003-08-07 DE DE60336326T patent/DE60336326D1/de not_active Expired - Lifetime
- 2003-08-07 US US10/524,235 patent/US7511140B2/en not_active Expired - Lifetime
- 2003-08-07 KR KR1020057002408A patent/KR101325827B1/ko active IP Right Grant
- 2003-08-07 CN CNB038239949A patent/CN100361979C/zh not_active Expired - Lifetime
- 2003-08-07 NZ NZ538070A patent/NZ538070A/en not_active IP Right Cessation
- 2003-08-07 CA CA2495296A patent/CA2495296C/en not_active Expired - Fee Related
- 2003-08-07 AT AT03784274T patent/ATE501125T1/de active
- 2003-08-07 BR BR0313394-0A patent/BR0313394A/pt not_active IP Right Cessation
- 2003-08-07 WO PCT/GB2003/003463 patent/WO2004014872A1/en active Application Filing
- 2003-08-07 SI SI200331993T patent/SI1539711T1/sl unknown
- 2003-08-07 PL PL03375296A patent/PL375296A1/xx unknown
- 2003-08-07 TW TW092121663A patent/TWI316058B/zh not_active IP Right Cessation
- 2003-08-07 PT PT03784274T patent/PT1539711E/pt unknown
- 2003-08-07 ES ES03784274T patent/ES2361009T3/es not_active Expired - Lifetime
- 2003-08-07 EP EP03784274A patent/EP1539711B1/en not_active Revoked
- 2003-08-07 AU AU2003251369A patent/AU2003251369B2/en not_active Expired
- 2003-08-11 MY MYPI20033048A patent/MY135301A/en unknown
- 2003-08-13 AR AR20030102929A patent/AR040868A1/es unknown
-
2005
- 2005-01-31 NO NO20050542A patent/NO329439B1/no not_active IP Right Cessation
- 2005-02-01 IL IL166626A patent/IL166626A/en unknown
- 2005-03-08 IS IS7728A patent/IS7728A/is unknown
-
2006
- 2006-01-10 ZA ZA200500745A patent/ZA200500745B/en unknown
- 2006-02-27 HK HK06102591A patent/HK1082735A1/xx not_active IP Right Cessation
-
2009
- 2009-02-13 US US12/371,359 patent/US7842807B2/en not_active Expired - Lifetime
-
2011
- 2011-05-09 CY CY20111100442T patent/CY1112412T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR040868A1 (es) | Proceso para la fabricacion de sal de calcio del acido (e)-7-[4-(4-fluorofenil)-6-isopropil-2-[metil (metilsulfonil) amino] piridin-5-il] (3r,5s)-3,5-dihidroxihept-6-enoico y producto que se obtiene a partir del mismo | |
MXPA05013128A (es) | Produccion mejorada de sal calcica de rosuvastatina. | |
IS2410B (is) | Kristallað bis[(E)-7-[4-(4-flúorófenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl) amínó] Pýrimidín-5-ýl](3R,5S)-3,5-díhýdroxýhept-6-enósýru]kalsíum salt | |
CO5670355A2 (es) | Forma cristalina de sal de calcio de acido bis [(e)-7-[4-(4-fluorofenil)-6-isopropil-2-[metil(metilsulfonil)amino]pirimidin-5-il](3r,5s)-3,5-dihidroxihept-6-enoico | |
DE60140581D1 (de) | Pharmazeutische Zusammensetzungen beinhaltend Kristallsalze von 7-Ä4-(4-Fluorophenyl)-6-isopropyl-2-Ämethyl(methylsulfonyl)aminoÜpyrimidin-5-ylÜ-(3R,5S)-3,5-dihydroxyhept-6-ensäure | |
GEP20022693B (en) | Pyrimidine Derivatives as HMG-Coa Reductase Inhibitors | |
IL175086A0 (en) | Process for the manufacture of the calcium salt of rosuvastatin (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl (methylsulfonyl) amino]pyrimidin-5-yl] 3r,5s)- 3,5-dihydroxyhept-6-enoic acid and crystalline intermediates thereof | |
CL2007001807A1 (es) | Composicion farmaceutica oral que comprende el acido (e)-7-[4-(4-fluorofenil)-6-isopropil-2-(metil-(metilsulfonil)-pirimidin-5-il]-(3r,5s)-3,5-dihodroxihept-6enoico, o una sal de ella y con una formulacion recubridora que contiene oxido ferrico; uso de la formulacion recubridora; util como inhibidor de hmg-coa reductasa. | |
UA89614C2 (ru) | Способ получения кальциевой соли розовастатина | |
UY27271A1 (es) | Composiciones farmacéuticas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |